Belgium Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Belgium Pharmaceuticals & Healthcare Report

The Belgium Pharmaceuticals and Healthcare Report

Independent 5-year pharmaceutical and healthcare industry forecasts for Belgium.

Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Belgian pharmaceutical and healthcare industry.

Competitive intelligence, Belgian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Belgian market.

The Belgium Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.

Business Monitor International’s Belgium Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Belgian pharmaceutical and healthcare industry.

Key Benefits of Report

Coverage

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.

Market Summary

Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.

Regulatory Regime

Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.

BMI 5-Year Industry Forecast

5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

BMI 5-Year Macroeconomic Forecasts

BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt

Competitive Landscape & Profiles

Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.

Belgium Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Table of Contents

Chapter - Executive Summary

Belgium Pharmaceuticals And Healthcare Industry SWOT
Belgium Political SWOT
Belgium Economic SWOT

Chapter - Pharmaceutical Business Environment Ratings

Table: Western Europe Pharmaceutical Business Environment Ratings
Limits Of Potential Returns

Chapter - Belgium – Market Summary

Regulatory Regime
Intellectual Property Environment
Pricing And Reimbursement Regime
Pricing And Reimbursement Developments

Chapter - Industry Developments

Healthcare Sector
Recent Healthcare Sector Developments
Epidemiology
Table: Disease Burden In Western Europe
Generics Sector
Research And Development Sector

Chapter - Industry Forecast Scenario

Overall Market Forecast
Table: Belgium's Drug Market Indicators, 2004-2013
Key Growth Factors – Industry
Table: Belgium's Health Expenditure Indicators, 2004-2013
Key Growth Factors – Macroeconomic
Table: Belgium - Economic Activity
Prescription Market Forecast
Table: ATC Breakdown Prescription Drug Market US$mn
Patented Market Forecast
Table: Belgium's Patented Drugs Market Indicators, 2004-2013
OTC Market Forecast
Table: Belgium's OTC Drugs Market Indicators, 2004-2013 (US$mn unless otherwise stated)
Generics Market Forecast
Table: Belgium's Generics Drug Market Indicators, 2004-2013
Export/Import Forecasts
Table: Belgium's Pharmaceuticals Exports And Imports, 2004-2013 (US$mn)
Other Healthcare Data Forecasts
Table: Belgium's Healthcare Data Indicators, 2005-2012
Key Risks To BMI's Forecasts

Chapter - Competitive Landscape

Recent Company Developments

Chapter - Company Monitor

Leading Multinational Manufacturers
GlaxoSmithKline (GSK)
Pfizer
Novartis
Sanofi-Aventis
Merck & Co
Leading Indigenous Manufacturers
UCB Pharma
Solvay
Janssen Pharmaceutica
Omega Pharma

Chapter - Country Snapshot: Belgium Demographic Data

Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2000-2012

Chapter - BMI Forecast Modelling

How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Belgium Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Executive Summary

BMI calculates Belgium’s pharmaceutical expenditure to have been EUR4.08bn (US$5.61bn) in 2008. By 2013, we expect the total amount spent on prescription and over-the-counter (OTC) medicines to have reached a value of EUR4.42bn equating to a compound annual growth rate (CAGR) of 1.8%. In US dollar terms, however, as a result of the weakening Euro, drug market expenditure will fall from US$5.61bn in 2009 to US$5.59bn in 2013.

In BMI’s all new Business Environment Rankings for Q209, Belgium has moved up to 3rd place in the Western Europe region. The Belgian pharmaceuticals market is among the top 5 in Western Europe and globally, Belgium is ranked in 5th position just behind Switzerland and Japan, after moving up 7 places in Q209.

Belgium has a relatively high per capita drug expenditure rate, at an estimated US$526 in 2008. However, a relatively stable population and rising social security expenditure have led the government to undertake severe measures to reduce expenditure on healthcare in general, and on pharmaceuticals in particular.

However, studies show that patients in Belgium pay significantly more for their medicines than those in other select European countries. A study carried out by the Belgian organisation Platform for Action for Health and Solidarity indicated that on average patients in Belgium pay 50% more for their medicines than patients in the Netherlands. For example, the most commonly prescribed drug for reducing cholesterol, Zocor (simvastatin), is five to seven times more expensive in Belgium than in the Netherlands. The most commonly prescribed drug to counteract stomach acid, Losec (omeprazole), is nine to 17 times more expensive in Belgium than in the Netherlands.

New regulations that came into effect in February 2009 allow patients in Belgium to buy non-prescription medicines online. Georges Gilinket, an MP for the Belgian political party Ecolo said that his party was very critical of the legislation as ‘taking medicines should not be trivialised and nothing should replace direct contact between a patient and their pharmacist’. There was also a concern that the development will encourage self-medication. Additionally, Belgium’s drugs agency – L’Agence Fédérale des Médicaments et des Produits de Santé (AFMPS) –expressed its concerns regarding health risks that may evolve as a result of patients purchasing medicines online via illegal networks.

Belgium Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Read about our other Pharmaceuticals & Healthcare Reports

Africa

Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe

Asia

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam

Caribbean

Puerto Rico

Europe

Belarus, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan

Latin America

Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela

Middle East

Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates

North America

Canada and United States
Business Monitor International Business Monitor International
A Market Leader in Country Risk, Industry Intelligence and Company Research

Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK

BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world.

Country Risk Analysis and Forecasts
BMI
has for 25 years specialised in political risk analysis, financial markets analysis, and macroeconomic forecasts on 175 global markets.

Industry Intelligence and Market Research
BMI's industry research covers Automotives; Banking; Chemicals; Defence & Security; Food & Drink; Freight Transport; Information Technology; Infrastructure; Insurance; Mining; Oil & Gas; Petrochemicals; Pharmaceuticals & Healthcare; Power; Telecommunications, and Tourism.

Company Research
BMI maintains a fully-researched 55,000-site database of multinational company subsidiaries located across global markets.